Aukerman G, Knutson D, Miser WF. Management of the acute migraine headache. Am Fam Physician. 2002 Dec;66(11):2123-2130. http://www.aafp.org. PMID: 12484694
Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS Task Force. Eur J Neurol. 2009 Sep;16(9):968-981. doi: 10.1111/j.1468-1331.2009.02748.x. PMID: 19708964
Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002 Jan;346(4):257-270. doi: 10.1056/NEJMra010917. PMID: 11807151
Schroeder BM. AAFP/ACP-ASIM release guidelines on the management and prevention of migraines. Am Fam Physician. 2003 Mar;67(6):1392-1397. http://www.aafp.org. PMID: 12674472
Morey SS. Guidelines on migraine: part 5. Recommendations for specific prophylactic drugs. Am Fam Physician. 2000 Dec;62(11):2535-2539. http://www.aafp.org. PMID: 11130237
Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr;78(17):1337-1345. doi: 10.1212/WNL.0b013e3182535d20. PMID: 22529202
Silberstein SD for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Sep;55(6):754-762. doi: 10.1212/wnl.55.6.754. PMID: 10993991
Snow V, Weiss K, Wall EM, Mottur-Pilson C; American Academy of Family Physicians; American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002 Nov;137(10):840-849. doi: 10.7326/0003-4819-137-10-200211190-00014. PMID: 12435222
Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of headache in adults. SIGN. http://www.sign.ac.uk. Nov 2008. Accessed 10 Feb 2011.
Ministry of Health (MOH) Singapore. Clinical practice guidelines: diagnosis and management of headache. MOH Singapore. http://www.moh.gov.sg. 2007.
Campbell JK, Penzien DB, Wall EM. Evidence-based guidelines for migraine headache: behavioral and physical treatments. American Academy of Neurology. https://www.aan.com. 25 Apr 2000.
MacGregor EA, Steiner TJ, Davies PTG for the British Association for the Study of Headache. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication-overuse headache. 3rd ed (1st rev). British Association for the Study of Headache. http://www.bash.org.uk. Sep 2010.
Beithon J, Gallenberg M, Johnson K, et al. Diagnosis and treatment of headache. Institute for Clinical Systems Improvement (ICSI). https://www.icsi.org. Jan 2013. Accessed 16 Apr 2015.
National Institute for Health and Clinical Excellence (NICE). Headaches: diagnosis and management of headaches in young people and adults. NICE clinical guideline 150. NICE. https://www.nice.org.uk. Sep 2012. Accessed 24 Apr 2015.
Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012 Mar;39(2)(Suppl 2):S1-S59. http://headachenetwork.ca. Accessed 20 Feb 2019. PMID: 22683887
Schwedt TJ, Garza I. Acute treatment of migraine in adults. UpToDate. https://www.uptodate.com. 07 Oct 2024. Accessed 04 Jun 2019.
Cutrer FM. Pathophysiology, clinical manifestations, and diagnosis of migraine in adults. UpToDate. https://www.uptodate.com. Nov 2018. Accessed 14 Oct 2019.
Peng KP, Wang SJ. Epidemiology of headache disorders in the Asia-Pacific region. Headache. 2014 Apr;54(4):610-618. doi: 10.1111/head.12328. Accessed 24 Mar 2017. PMID: 24666014
Robertson CE, Black DF, Swanson JW. Management of migraine headache in the emergency department. Semin Neurol. 2010 Apr;30(2):201-211. doi: 10.1055/s-0030-1249228. Accessed 2 May 2017. PMID: 20352590
World Health Organization (WHO). Headache disorders. WHO. https://www.who.int. Apr 2016. Accessed 24 Mar 2017.
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi: 10.1177/0333102417738202. Accessed 20 Feb 2018. PMID: 29368949
Becker WJ, Findlay T, Moga C, et al. Guideline for primary care management of headache in adults. Can Fam Physician. 2015 Aug;61(8):670-679. Accessed 20 Feb 2019. PMID: 26273080
Institute of Health Economics Alberta Canada. Primary care management of headache in adults clinical practice guideline. Institute of Health Economics Alberta Canada. https://www.ihe.ca/. Sep 2016. Accessed 20 Feb 2019.
American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019 Jan;59(1):1-18. doi: 10.1111/head.13456. Accessed 22 Feb 2019. PMID: 30536394
Bajwa ZH, Smith JH. Preventive treatment of migraine in adults. UpToDate. https://www.uptodate.com. Dec 2018. Accessed 28 Feb 2019.
Diener HC, Holle-Lee D, Nägel S, et al. Treatment of migraine attacks and prevention of migraine: guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clinical and Translational Neuroscience. 2019:1-40. doi: 10.1177/2514183X18823377. Accessed 04 Jun 2019
MacGregor A. Management of migraine during pregnancy. Progress in Neurology and Psychiatry banner. 2009 Oct;13(5):21-24. doi: 10.1002/pnp.137. Accessed 04 Jun 2019
National Institute for Health and Clinical Excellence (NICE). Botulinum toxin type A to prevent chronic migraine headaches. NICE. http://www.nice.org.uk. Jun 2012. Accessed 04 Jun 2019.
Robbins MS. Migraine in pregnancy. American Headache Society. http://www.americanheadachesociety.org. Accessed 04 Jun 2019.
Gilmore B, Michael M. Treatment of acute migraine headache. Am Fam Physician. 2011 Feb;83(3):271-280. PMID: 21302868
Hainer B, Matheson E. Approach to acute headaches in adults. Am Fam Physician. 2013 May;87(10):682-687. http://www.aafp.org. Accessed 23 Apr 2015. PMID: 23939446
Lipton RB, Diener H, Robbins MS, et al. Caffeine in the management of patients with headache. J Headache Pain. 2017;18(1):107. doi: 10.1186/s10194-017-0806-2. Accessed 03 Sep 2019. PMID: 29067618
U.S. Food & Drug Administration (US FDA). FDA approves new treatment for patients with migraine. US FDA. https://www.fda.gov. 11 Oct 2019. Accessed 07 Nov 2019.
Calhoun AH. Estrogen-associated migraine. UpToDate. https://www.uptodate.com. 17 Dec 2018. Accessed 27 Jun 2019.
Carmona S, Bruera O. Prophylactic treatment of migraine and migraine clinical variants with topiramate: an update. Ther Clin Risk Manag. 2009;5:661-669. Accessed 23 Oct 2019. PMID: 19707282
Chawla J. Migraine headache. Medscape. https://emedicine.medscape.com. 21 Oct 2019. Accessed 23 Oct 2019.
Deleu D, Hanssens Y. Guidelines for the prevention of migraine. Neurosciences (Riyadh). 2000 Jan;5(1):7-12. PMID: 24276654
Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat. 2013;9:709-720. doi: 10.2147/NDT.S33769. PMID: 23717045
Lipchik GL. Biofeedback and relaxation training for headaches. American Migraine Foundation. https://americanmigrainefoundation.org. 12 Nov 2016. Accessed 30 Oct 2019.
Loder E, Burch R and Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012 Jun;52(6):930-945. doi: 10.1111/j.1526-4610.2012.02185.x. PMID: 22671714
Mikkelsen B, Pedersen KK, Christiansen LV. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neurol Scand. 1986 Apr;73(4):423-427. doi: 10.1111/j.1600-0404.1986.tb03299.x. PMID: 3727918
National Institute for Health and Care Excellence (NICE). Management of migraine (with or without aura). NICE. https://www.nice.org.uk/.
Orr SL, Aube M, Becker WJ, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015 Mar;35(3):271-284. doi: 10.1177/0333102414535997. Accessed 23 Oct 2019. PMID: 24875925
Silberstein SD, Saper JR, Freitag FG. Migraine diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DE, eds. Wolff’s Headache and Other Head Pain. 7th ed. Oxford, England: Oxford University Press; 2001. 121-237. :121-237.
Worthington I, Pringsheim T, Gawel MJ, et al on behalf of the Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013 Sep;40(5)(Suppl 3):S1-S80. Accessed 23 Oct 2019. PMID: 23968886
Cutrer FM. Pathophysiology, clinical manifestations, and diagnosis of migraine in adults. UpToDate. https://www.uptodate.com. 05 Nov 2020.
Garza I, Schwedt TJ. Chronic migraine. UpToDate. https://www.uptodate.com. 03 Oct 2024. Accessed 13 Feb 2021.
Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019 Jan;20(1):6. doi: 10.1186/s10194-018-0955-y. Accessed 13 Feb 2021. PMID: 30651064
Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the global campaign against headache. J Headache Pain. 2019 May;20(1):57. doi: 10.1186/s10194-018-0899-2. Accessed 13 Feb 2021. PMID: 31113373
Ailani J, Lipton RB, Goadsby PJ, et al; ADVANCE Study Group. Atogepant for the Preventive Treatment of Migraine. N Engl J Med. 2021 Aug;385(8):695-706. doi: 10.1056/NEJMoa2035908. PMID: 34407343
Atogepant receives FDA approval for the preventive treatment of episodic migraine in adults [Internet] American Headache Society ; 2021 OctAvailable from: https://americanheadachesociety.org/news/atogepant-receives-fda-approval-for-the-preventive-treatment-of-episodic-migraine-in-adults/
Schwedt TJ, Garza I. Preventive treatment of episodic migraine in adults. UpToDate. https://www.uptodate.com. 02 Jan 2025. Accessed 25 Jan 2022.
Tepper D. Gepants. Headache. 2020 May;60(5):1037-1039. doi: 10.1111/head.13791. PMID: 32337726
Scottish Intercollegiate Guidelines Network (SIGN). SIGN 155: Pharmacological management of migraine. A national clinical guideline. SIGN. https://www.sign.ac.uk/. Mar 2023.
Charles AC, Digre KB, Goadsby PJ, et al; American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024 Apr;64(4):333-341. doi: 10.1111/head.14692. PMID: 38466028
Li XY, Yang CH, Lv JJ, et al. Global, regional, and national epidemiology of migraine and tension-type headache in youths and young adults aged 15-39 years from 1990 to 2019: findings from the global burden of disease study 2019. J Headache Pain. 2023 Sep;24(1):126. doi: 10.1186/s10194-023-01659-1. PMID: 37718436
Steiner TJ, Stovner LJ, Jensen R, et al; Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec;21(1):137. doi: 10.1186/s10194-020-01208-0. PMID: 33267788
World Health Organization (WHO). Migraine and other headache disorders. WHO. https://www.who.int/. Mar 2024.
Roxas Jr AA, Quiles LE, Diamante PA. The practice patterns of migraine management among neurologists in the Philippines - a cross-sectional survey. Neurology Asia. 2022;27(3):717-724. https://doi.org/10.54029/2022azf.
Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-514. doi: 10.1038/s41582-021-00509-5. PMID: 34145431
Sánchez-Rodríguez C, Sierra Á, Planchuelo-Gómez Á, et al. Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study. Sci Rep. 2021 Feb;15(11):3846. doi: 10.1038/s41598-021-83508-2. PMID: 33589682
Qaseem A, Tice JA, Etxeandia-Ikobaltzeta I, et al. Pharmacologic treatments of acute episodic migraine headache in outpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med. 2025 Apr;178(4):571-578. doi: 10.7326/ANNALS-24-03095. PMID: 40096690
Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, et al. Prevention of episodic migraine headache using pharmacologic treatments in outpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med. 2025 Mar;178(3)(Suppl 426-433). doi: 10.7326/ANNALS-24-01052. PMID: 39899861
Amiri P, Kazeminasab S, Nejadghaderi SA, et al. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol. 2022 Feb;12:800605. doi: 10.3389/fneur.2021.800605. PMID: 35281991
Hernandez J, Molina E, Rodriguez A, et al. Headache disorders: differentiating primary and secondary etiologies. J Integr Neurosci. 2024 Feb;23(2):43. doi: 10.31083/j.jin2302043. PMID: 38419454
